Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) EPS (Basic) (2020 - 2026)

Edgewise Therapeutics has reported EPS (Basic) over the past 7 years, most recently at -$0.46 for Q1 2026.

  • Quarterly results put EPS (Basic) at -$0.46 for Q1 2026, down 6.98% from a year ago — trailing twelve months through Mar 2026 was -$1.67 (down 7.74% YoY), and the annual figure for FY2025 was -$1.63, down 12.41%.
  • EPS (Basic) reached -$0.46 in Q1 2026 per EWTX's latest filing, up from -$0.48 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.3 in Q1 2022 and bottomed at -$0.48 in Q4 2025.
  • Median EPS (Basic) over the past 5 years was -$0.36 (2023), compared with a mean of -$0.38.
  • The largest annual shift saw EPS (Basic) soared 93.14% in 2022 before it crashed 56.67% in 2023.
  • Over 5 years, EPS (Basic) stood at -$0.3 in 2022, then tumbled by 56.67% to -$0.47 in 2023, then grew by 10.64% to -$0.42 in 2024, then fell by 14.29% to -$0.48 in 2025, then rose by 4.17% to -$0.46 in 2026.
  • Business Quant data shows EPS (Basic) for EWTX at -$0.46 in Q1 2026, -$0.48 in Q4 2025, and -$0.39 in Q3 2025.